Ireland: IPHA And The Government Finally Reach Agreement On The Supply And Pricing Of Medicines In Ireland

Last Updated: 22 August 2016
Article by Colin Kavanagh and Ciara Farrell

On 20 July 2016, following much debate and lengthy negotiations, the Irish Government, the Health Service Executive ("HSE") and the Irish Pharmaceutical Healthcare Association ("IPHA") signed the Framework Agreement on the Supply and Pricing of Medicines (the "Agreement") .


The new Agreement, which came into effect on 1 August 2016, governs the supply and pricing of medicinal products that are included on the HSE Reimbursement List , supplied to, or reimbursed by, the HSE, State-funded hospitals or any other publicly-funded entities and State agencies providing similar services ("Hospital Medicines"), or subject to an application for inclusion on the Reimbursement List, or for supply or reimbursement as a Hospital Medicine.


The previous Agreement stated that the agreement applied to "all suppliers" of products that fall within the scope above. However, the 2012 Agreement did not define the term "supplier" nor did it differentiate between IPHA member companies and non-IPHA member companies.

The new Agreement applies only to IPHA member companies (listed in Schedule 2 of the Agreement). The HSE and IPHA member companies may now only rely on the provisions of the new Agreement by agreement.

We would anticipate that many non- IPHA members will take account of the pricing criteria in the new Agreement when submitting an application for pricing approval or come to their own arrangements with the HSE. This would not depart radically from previous practice under the 2012 Agreement.


Section 21(2) of the Health (Pricing and Supply of Medical Goods) Act 2013 (the "2013 Act") allows the HSE to take account of a number of different factors, only one of which is the terms of the Agreement, when considering the proposed price of a product submitted by a supplier.

The Agreement purports to reflect this position by stating that the Agreement does not create legal relations or legitimate expectations which can be enforced by or against the parties. The Agreement also states that it will not limit the HSE's powers under the 2013 Act, allowing the HSE to take into account other factors when assessing the proposed price of a medicinal product.


Outlined below are a number of notable differences between the new more comprehensive Agreement and its predecessor.

Four year term

The Agreement is for a period of four years rather than the previous three year term.

Extension of the number of nominated EU Member States

Under the previous Agreement, prices were set at the average of the currency-adjusted ex-factory price (price to wholesaler) in nine EU Member States, namely, Austria, Belgium, Denmark, Finland, France, Germany, the Netherlands, Spain and the UK. The new Agreement introduces five additional EU Member States (Greece, Italy, Luxembourg, Portugal and Sweden), bringing the proposed price of a product in line with the average ex-factory price in 14 Member States.

Annual price realignment

All medicinal products will now be subject to an annual price realignment commencing on 1 August 2016 and on 1 July for each subsequent year. The price realignment will be set as the average ex-factory price of the 14 Member States.

The price realignments will be downwards only. The HSE and the suppliers should have agreed new prices for 2016 no later than 20 July 2016.

Rebates increase

Rebates from suppliers to the HSE for products will increase from 4% to 5.25% (1 June 2016 – 31 July 2018) and 5.5% (1 August 2018 – 31 July 2020) of the ex-factory price. It is intended that further guidance in relation to the payment and collection of rebates with regard to Hospital Medicines will be developed by the HSE and IPHA.

Reduction in price of patent-expired products

The price of a medicinal product that has lost patent protection and for which a generic product is available will fall to 50% of the original ex-factory price.

Similar to the 2012 Agreement, the HSE will notify the supplier when a generic medicinal product has become available and the date from which the new price will apply, which will be no less than 28 days following notification.

Reduction in price of patent-expired biological products

For the first time, the Agreement differentiates between generic medicinal products and biosimilar products when considering price reductions for patent-expired products. Patent-expired biological products will now be subject to a 20% reduction in price once a biosimilar enters the market.

In addition to the price cut and, unlike generic medicinal products, suppliers of biological products must pay the HSE a rebate of 12.5% of the value of the reduced price.

Penalties related to continuity of supply

Under the 2012 Agreement, suppliers in breach of the provisions related to continuity of supply, such as notice periods, were required to either source and supply alternative equivalent products at the same price as the unavailable product or reimburse the HSE any difference in cost arising from the shortage.

The new Agreement no longer includes this provision. However, the Agreement mentions that suppliers must adhere to the IPHA/HSE Statement of Best Practice for Notifying the Discontinuation of a Medicine from the Irish Market ("Best Practices") which still includes these penalties. Suppliers should monitor any amendments to the Best Practices.

Guidance and transparency when assessing new medicinal products

Schedule 1 of the Agreement sets out detailed principles and processes for the assessment of pricing and reimbursement of new products in Ireland. The new principles and processes provide some clarity and transparency with regard to the decision making structure and timelines. The new Agreement formalises the Annual Horizon Scan, the Rapid Review Process and provides clarity in relation to the HSE Drugs Group recommendations.

One of the most notable changes in the decision making process is the introduction of the role of the Department of Health and the Government when reviewing products which cannot be funded from within existing HSE resources, such as products that exceed the budget impact or a certain cost-effectiveness threshold. At the first instance, the HSE Leadership will assess such products. If the HSE cannot reimburse the product, the HSE can inform the Department of Health who, in turn, may apply to the Government to request consideration of the funding of the product. It is hoped that more clarity as to the practical application of such a high level review for specific products will be provided once the Agreement comes into force.

This article contains a general summary of developments and is not a complete or definitive statement of the law. Specific legal advice should be obtained where appropriate.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.